Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry

Myofascial Pain Clinical Trial

— MitoTrigger  

Official title:

Evaluation of Mitochondrial Function in Chronic Myofascial Trigger Points - A Prospective Cohort Pilot Study Using High-resolution Respirometry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03704311
• Other study ID #: MUInnsbruck
• Status: Completed
• Phase: N/A
• Start date: October 1, 2013
• Est. completion date: December 1, 2014

Study information

• Verified date: October 2018
• Source: Medical University Innsbruck
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study established a minimally invasive biopsy technique to obtain high-quality MTrP tissue samples to evaluate mitochondrial function via high-resolution respirometry.

Description:

Myofascial trigger points (MTrPs) are hyperirritable areas in the fascia of the affected muscle, possibly related to mitochondrial impairment. They can result in pain and hypoxic areas within the muscle. This pilot study established a minimally invasive biopsy technique to obtain high-quality MTrP tissue samples to evaluate mitochondrial function via high-resolution respirometry. Secondary objectives included the safety of the biopsy procedure assessed via clinical wound healing (number of patients with signs for local infection and inflammation). For this purpose, twenty healthy males participated in this study, 10 with a diagnosis of myofascial pain in the musculus (m.) trapezius MTrP (TTP group) and 10 with a diagnosis of myofascial pain in the m. gluteus medius (GTP group). The affected muscle was biopsied followed by a biopsy from the vastus lateralis to be used as a control. Measurements of oxygen consumption were carried out using high-resolution respirometry.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 1, 2014
• Est. primary completion date: February 1, 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male patients aged 18-45 years

• Clinical diagnosis of myofascial pain syndrome within the region of the shoulder-neck muscles or the lumbogluteal region and the presence of an MTrP, defined as a firm palpation of a hard, tender nodule resulting in a spontaneous pain complaint

• with symptoms present for 1 to 12 months

Exclusion Criteria:

• Signs that the participant's prescriptive compliance was not expected (e.g., lack of cooperation)

• Disorders of the respiratory tract

• Neurological disorders, in particular neurodegenerative and neuromuscular diseases

• Disorders of the cardiovascular system or the musculoskeletal system

• Civil servants and military service personnel.

Related Conditions & MeSH terms

• Back Pain
• Mitochondrial Pathology
• Myofascial Pain
• Myofascial Pain Syndromes
• Myofascial Trigger Point Pain
• Neck Pain
• Pain, Back
• Pain, Neck

Intervention

Procedure:
• Muscle biopsy
Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Medical University Innsbruck

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mitochondrial function in myofascial trigger points	Mitochondrial respiration was assessed from muscle biopsy samples obtained from trigger points of the musculus trapezius and the musculus gluteus medius	Baseline measurement
Secondary	Number of participants with biopsy-related impaired wound healing	Clinical wound assessment (number of patients with signs for local infection and inflammation)	Baseline and follow-up assessment (1 week after the baseline biopsy)